HealthcareServices

Malignant Mesothelioma Industry Poised for Rapid Growth, Forecast to Touch $3.53 Billion by 2030 at 6.3% CAGR

February 26, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the malignant mesothelioma market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Malignant Mesothelioma Market in 2030?

The malignant mesothelioma market size has demonstrated significant expansion in recent years. It is projected to expand from $2.61 billion in 2025 to $2.77 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. This growth observed in the historical period is attributable to past asbestos exposure in construction and manufacturing industries, the disease’s lengthy latency period, scarcity of early treatment solutions, increasing recognition of occupational health issues, and continuous advancements in diagnostic imaging.

The market size for malignant mesothelioma is projected to experience substantial growth over the coming years, expanding to $3.53 billion by 2030 with a compound annual growth rate (CAGR) of 6.3%. This forecasted growth can be attributed to advancements in immunotherapy and targeted drugs, increasing investment in rare cancer research, a rising number of clinical trials, enhancements in diagnostic technologies, and higher healthcare spending on oncology. Significant trends expected during this period include the growing adoption of immunotherapy and targeted therapy, an increasing focus on multimodal treatment approaches, a greater demand for early and accurate diagnosis, the expansion of specialized mesothelioma treatment centers, and higher participation in clinical trials for rare cancers.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22046&type=smp

What Drivers Are Influencing Production Trends In The Malignant Mesothelioma Market?

Enhanced clinical research and development (R&D) initiatives are anticipated to propel the expansion of the malignant mesothelioma market moving forward. Clinical R&D involves undertaking scientific investigations and trials with the aim of creating novel pharmaceuticals, therapies, and medical equipment. These efforts include evaluating the safety, effectiveness, and potential adverse reactions of new products through structured clinical trials. The surge in clinical R&D is attributed to the escalating demand for innovative and enhanced treatments, particularly given the increasing occurrence of chronic illnesses and intricate medical conditions. Research and development efforts contribute to the malignant mesothelioma market by speeding up advancements in diagnostics, therapeutic approaches, and precision medicine, thereby encouraging novel methods for earlier detection, better survival outcomes, and the creation of more potent, less intrusive treatment alternatives. For instance, in January 2025, according to Anadolu Agency, a Turkey-based state-run news agency, clinical trials account for nearly 40% of the U.S. pharmaceutical research budget, amounting to approximately $7 billion annually. Consequently, the escalating R&D endeavors are fueling the growth of the malignant mesothelioma market.

Which Segment Groups Are Influencing The Malignant Mesothelioma Market?

The malignant mesothelioma market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Radiation Therapy, Surgery, Immunotherapy, Targeted Therapy

2) By Route Of Administration: Oral, Intravenous, Injectable

3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

4) By End-User: Hospitals, Oncology Clinics

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Combination Therapy

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy

3) By Surgery: Pleurectomy Or Decortication (P/D), Extrapleural Pneumonectomy (EPP), Cytoreductive Surgery, Palliative Surgery

4) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Tumor Vaccines, Adoptive Cell Therapy

5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Angiogenesis Inhibitors, Mesothelin-Targeted Agents, Gene Therapy-Based Approaches

What Trends Are Projected To Support The Growth Of The Malignant Mesothelioma Market?

Major companies operating in the malignant mesothelioma market are focusing on developing advanced treatment options, such as monoclonal antibody treatments, to impede tumor growth and enhance treatment precision. Monoclonal antibodies are laboratory-crafted proteins designed to mimic the immune system’s capability to detect and target specific antigens, like those found on cancer cells. For instance, in November 2023, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, secured supplemental approval in Japan for the expanded application of Opdivo (nivolumab), a human anti-human PD-1 monoclonal antibody for the management of malignant mesothelioma (excluding malignant pleural mesothelioma). This approval positions Opdivo as a novel therapeutic option for this condition, for which no standard treatments were previously available. Opdivo was designated an orphan drug for this indication, emphasizing its potential to address a significant medical need.

Who Are The Primary Competitors In The Global Malignant Mesothelioma Market?

Major companies operating in the malignant mesothelioma market are AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Gilead Sciences Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Bayer AG, Eisai Co. Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co. Ltd., PharmaMar S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/malignant-mesothelioma-global-market-report

Which Regions Are Poised For Strategic Growth In The Malignant Mesothelioma Market?

North America was the largest region in the malignant mesothelioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Malignant Mesothelioma Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22046&type=smp

Browse Through More Reports Similar to the Global Malignant Mesothelioma Market 2026, By The Business Research Company

Adult Malignant Glioma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Acoustic Neuroma Market Report 2026

https://www.thebusinessresearchcompany.com/report/acoustic-neuroma-global-market-report

Paraganglioma Market Report 2026

https://www.thebusinessresearchcompany.com/report/paraganglioma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795